GlassScriptPhysician profile
Jere D Claunch
NPI 1518977867
$15,062.98
in general payments reported to CMS, 2019-2025
68 companies · $1,984 in 2025
The $1,984 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,018 · 2022: $1,932 · 2023: $2,881 · 2024: $3,247 · 2025: $1,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,113.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,586.17 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $1,017.87 | 2021-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $1,005.00 | 2021-2025 | |
| Axsome Therapeutics, INC. | $919.91 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $874.11 | 2021-2025 | Spravato |
| Esperion Therapeutics, INC. | $783.96 | 2021-2025 | Nexletol |
| Lundbeck LLC | $630.05 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $588.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corium, LLC | $526.89 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $511.78 | 2021-2023 | Belsomra |
| Amgen INC. | $426.17 | 2021-2025 | Otezla, Repatha, Evenity |
| Daiichi Sankyo INC. | $349.24 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $280.64 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.61 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $250.13 | 2021-2023 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jere Claunch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.